^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABSK043

    i
    Other names: ABSK043, ABSK-043, ABSK 043
    Associations

    News

    Trials
    Company:
    Abbisko
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    14d
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib (clinicaltrials.gov)
    P2, N=54, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Nov 2024 | Trial primary completion date: Jun 2027 --> Dec 2027
    Enrollment open • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    Ivesa (firmonertinib) • ABSK043
    1m
    A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
    P2, N=202, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 overexpression • FGF3 overexpression
    |
    ABSK043 • ABSK061
    2ms
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P2 trial • Combination therapy • Metastases
    |
    Ivesa (firmonertinib) • ABSK043
    3ms
    A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
    P2, N=202, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    New P2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    FGFR3 overexpression • FGF3 overexpression
    |
    ABSK043 • ABSK061
    over1year
    First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors (ESMO 2023)
    On-target PD effects were consistent with PD-L1 inhibition and data reported by anti-PD-(L)1 mAbs. Preliminary anti-tumor activity was observed, and further studies are warranted to explore the efficacy in a larger number of patients.
    Clinical • P1 data • Metastases
    |
    MSI (Microsatellite instability) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL2 (Interleukin 2)
    |
    MSI-H/dMMR
    |
    ABSK043
    2years
    Broad anti-tumor activity of a potent and selective small molecule antagonist of PD-L1 ABSK043 in combination with other agents in preclinical models (SITC 2022)
    Results ABSK043 demonstrated strong in vivo synergy with several therapeutic agents such as carboplatin, a key component of the widely used CRC standard-of care chemotherapy treatment regimen, as well as other target therapy or immune-oncology agents. Conclusions Taken together, these data for the first time demonstrated broad combination synergy of a small molecule PD-L1 antagonist with other agents and provided basis for potential clinical evaluation of these combination treatment for cancer patients.
    Preclinical • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • ABSK043
    over2years
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=60, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    ABSK043
    over3years
    A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Abbisko Therapeutics Co, Ltd
    Clinical • New P1 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    ABSK043